United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $518.96, for a total value of $4,930,120.00. Following the transaction, the chief executive officer owned 324,443 shares of the company’s stock, valued at $168,372,939.28. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Price Performance

NASDAQ UTHR traded down $1.40 during trading on Monday, reaching $516.31. 427,626 shares of the company’s stock were exchanged, compared to its average volume of 484,638. The business has a 50 day moving average price of $543.63 and a 200-day moving average price of $532.79. The stock has a market capitalization of $21.92 billion, a P/E ratio of 19.06, a PEG ratio of 1.73 and a beta of 0.59. United Therapeutics Corporation has a fifty-two week low of $287.64 and a fifty-two week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period in the previous year, the business earned $6.63 earnings per share. The business’s quarterly revenue was down 1.6% on a year-over-year basis. On average, analysts forecast that United Therapeutics Corporation will post 26.65 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have issued reports on UTHR shares. Raymond James Financial initiated coverage on United Therapeutics in a report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Wells Fargo & Company upgraded shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Weiss Ratings downgraded shares of United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. Finally, Royal Bank Of Canada raised their target price on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $648.33.

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. boosted its stake in United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Northwestern Mutual Wealth Management Co. increased its position in United Therapeutics by 18.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock worth $127,000 after buying an additional 70 shares during the period. Jump Financial LLC acquired a new stake in shares of United Therapeutics during the second quarter worth $277,000. Cerity Partners LLC lifted its holdings in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia boosted its position in shares of United Therapeutics by 6.9% in the second quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares during the period. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.